William Blair Initial Report on Collegium

19 February, 2016

Collegium Pharmaceutical, Inc.

Initiating Coverage With an Outperform Rating and $35 Price Target

Collegium Pharmaceutical is a development-stage specialty pharmaceutical company with expertise in developing abuse-deterrent products for the treatment of chronic pain and other areas where drug abuse and diversion has become a significant issue. The company’s lead product, Xtampza ER, an extended-release oxycodone-based product with abuse-deterrent technology (ADT), has received tentative approval from the FDA for the treatment of chronic pain that requires around-the-clock opioid analgesia for an extended period.

 
Related News
William Blair Initial Report on Collegium
02.19.16
Initiating Coverage With an Outperform Rating and $35 Price Target Read Full Release
BMP Portfolio Company Collegium Announces Favorable Judgment by the District Court of Massachusetts
02.11.16
CANTON, Mass., Feb. 11, 2016 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announced that the District Court of Massachusetts issued an order for final judgment in favor of Collegium and against plaintiffs Purdue Pharma L.P., The P.F. Laboratories, Inc., Purdue Pharmaceuticals L.P., and Rhodes Technologies. The judgment relates to Purdue’s three Orange Book-listed patents asserted against Collegium that were the cause of the 30 month stay imposed on our New Drug Application for Xtampza™ ER... Read Full Release
Collegium Announces FDA Tentative Approval for Xtampza(TM) ER, a Novel Abuse-Deterrent Analgesic for Chronic Pain
11.09.15
Collegium Pharmaceutical, Inc. (Nasdaq:COLL) announces that the United States Food and Drug Administration (FDA) has granted tentative approval to the Company's New Drug Application (NDA) for Xtampza™ ER (oxycodone) extended-release capsules. Read Full Release
Boston Millennia Portfolio Company, Collegium Pharmaceutical Raises $50 million Financing
03.10.15
Collegium Pharmaceutical, Inc., today announced that it has raised a $50 million financing. Collegium plans to use the proceeds of this financing to advance its lead abuse-deterrent product candidate, Xtampza ER through potential FDA approval and commercial launch as well as to fund operational growth and other pipeline development programs. Read Full Release
Millennia Portfolio Company, Collegium Pharmaceutical, Announces Positive Top-Line Data from Phase III Study of Oxycodone DETERx®
08.06.14
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, today announced positive top-line results from its pivotal Phase 3 study of the company’s investigational analgesic Oxycodone DETERx® that studied the treatment of patients with moderate-to-severe chronic low back pain. Read Full Release
Boston Millennia Partners Congratulates PreCision Dermatology Management on $500 Million Sale to Valeant Pharmaceuticals International
07.07.14
With the receipt of Hart-Scott-Rodino clearance, the previously announced acquisition of Precision Dermatology by Valeant Pharmaceuticals International, Inc. for $500 million, closed July 7, 2014. Read Full Release
Millennia Portfolio Company, Collegium Pharmaceutical, Completes Successful IPO
05.12.14
Millennia Portfolio Company, Collegium Pharmaceutical Inc., a specialty pharmaceutical company developing abuse-deterrent products, announced the closing of its initial public offering of 6,670,000 shares of its common stock at a price to the public of $12.00 per share. (Nasdaq:COLL) Read Full Release
Boston Millennia Portfolio Company, Collegium Pharmaceutical, Featured in Wall Street Journal
05.06.13
Collegium Pharmaceutical was featured in a Wall Street Journal article discussing the innovative technologies being developed in the painkiller market to make drugs more abuse-deterrent. Read Full Release
Boston Millennia Partners Portfolio Company, Collegium Pharmaceuticals, Announces Successful Completion of Clinical Study
04.17.13
Millennia Portfolio Company, Collegium Pharmaceuticals, announced today the top-line results from its completed Phase I clinical trial for Oxycodone DETERx®, its extended-release, abuse-deterrent, multi-particulate product in a capsule form. Read Full Release